secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001140361-25-029860
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4
--------------------------------------------------------------------------------

- Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.
- Cash $3.2M, accumulated deficit $137.7M; expects current cash to fund ops into early Q4 2025.
- EU MDR approval for FemBloc non-surgical birth control; first $400K order from Spain.
- Australia/New Zealand approvals for FemaSeed and FemVue; partnered with Carolinas Fertility Institute.
- Closed $4.5M public offering and private placement for working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125029860/0001140361-25-029860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125029860/ef20053541_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-029860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer